FI3909972T3 - Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä - Google Patents
Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä Download PDFInfo
- Publication number
- FI3909972T3 FI3909972T3 FIEP21155542.0T FI21155542T FI3909972T3 FI 3909972 T3 FI3909972 T3 FI 3909972T3 FI 21155542 T FI21155542 T FI 21155542T FI 3909972 T3 FI3909972 T3 FI 3909972T3
- Authority
- FI
- Finland
- Prior art keywords
- cell
- polypeptide
- sequence
- cancer
- use according
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims 6
- 102000037865 fusion proteins Human genes 0.000 title claims 6
- 239000003814 drug Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000005619 esophageal carcinoma Diseases 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3909972T3 true FI3909972T3 (fi) | 2024-05-03 |
Family
ID=53476720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21155542.0T FI3909972T3 (fi) | 2015-06-19 | 2016-06-20 | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (enExample) |
| EP (3) | EP3310805B1 (enExample) |
| JP (3) | JP7085988B2 (enExample) |
| CN (3) | CN115925971A (enExample) |
| AU (1) | AU2016277883B2 (enExample) |
| CA (1) | CA2989949A1 (enExample) |
| DK (2) | DK3909972T5 (enExample) |
| ES (2) | ES2976647T3 (enExample) |
| FI (1) | FI3909972T3 (enExample) |
| HU (1) | HUE054201T2 (enExample) |
| PL (1) | PL3310805T3 (enExample) |
| PT (1) | PT3310805T (enExample) |
| WO (1) | WO2016203048A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| HK1255637A1 (zh) * | 2015-06-29 | 2019-08-23 | The Johns Hopkins University | 免疫检查点嵌合受体疗法 |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| EP3478722A1 (en) * | 2016-06-30 | 2019-05-08 | F. Hoffmann-La Roche AG | Improved adoptive t-cell therapy |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| WO2018119298A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| EP4043485A1 (en) * | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| AU2019231205A1 (en) * | 2018-03-06 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| TW202042824A (zh) * | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| CA3211402A1 (en) * | 2021-03-10 | 2022-09-15 | Moshe ELKABETS | Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules |
| CN120988097A (zh) * | 2021-04-11 | 2025-11-21 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| WO2022246053A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| EP4619424A2 (en) * | 2022-11-14 | 2025-09-24 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN107188969B (zh) | 2011-04-08 | 2021-08-27 | 美国卫生和人力服务部 | 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| KR101471647B1 (ko) | 2011-10-26 | 2014-12-11 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| WO2013062365A2 (ko) | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| CA3209571A1 (en) | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3039040B1 (en) | 2013-08-26 | 2021-12-22 | Hinrich Abken | Anti cd30 chimeric antigen receptor and its use |
| BR112017011771A2 (pt) | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| WO2019051128A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF |
| CN115418362B (zh) * | 2019-12-02 | 2025-06-13 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
-
2021
- 2021-10-29 US US17/515,250 patent/US20220169699A1/en active Pending
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2976647T3 (es) | 2024-08-06 |
| EP4349854A2 (en) | 2024-04-10 |
| PT3310805T (pt) | 2021-05-19 |
| AU2016277883B2 (en) | 2020-09-17 |
| EP3909972A1 (en) | 2021-11-17 |
| DK3909972T5 (da) | 2024-08-05 |
| US20220169699A1 (en) | 2022-06-02 |
| US11192935B2 (en) | 2021-12-07 |
| EP3310805B1 (en) | 2021-02-17 |
| PL3310805T3 (pl) | 2021-08-23 |
| AU2016277883A1 (en) | 2018-01-18 |
| HUE054201T2 (hu) | 2021-08-30 |
| JP2022084787A (ja) | 2022-06-07 |
| EP3909972B1 (en) | 2024-02-14 |
| CN108026151A (zh) | 2018-05-11 |
| EP4349854A3 (en) | 2024-07-10 |
| DK3909972T3 (da) | 2024-04-29 |
| CA2989949A1 (en) | 2016-12-22 |
| US20190010207A1 (en) | 2019-01-10 |
| JP7085988B2 (ja) | 2022-06-17 |
| CN115927474A (zh) | 2023-04-07 |
| WO2016203048A1 (en) | 2016-12-22 |
| CN115925971A (zh) | 2023-04-07 |
| JP2024073636A (ja) | 2024-05-29 |
| JP2018518990A (ja) | 2018-07-19 |
| JP7460675B2 (ja) | 2024-04-02 |
| EP3310805A1 (en) | 2018-04-25 |
| AU2016277883A8 (en) | 2018-01-25 |
| DK3310805T3 (da) | 2021-05-03 |
| CN108026151B (zh) | 2022-07-15 |
| ES2870174T3 (es) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2016534717A5 (enExample) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| IL318172A (en) | Enhanced chimeric antigen receptors and uses thereof | |
| IL276593A (en) | Improved methods for producing adoptive cell therapies | |
| Lee et al. | Human γδ T cell subsets and their clinical applications for cancer immunotherapy | |
| JP2018518990A5 (enExample) | ||
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| HRP20240494T1 (hr) | Kimerni antigenski receptori specifični za bcma i njihove upotrebe | |
| FI3227432T3 (fi) | B-solujen kypsymisantigeeniin kohdistuvia kimeerisiä antigeenireseptoreita ja niiden käyttötarkoituksia | |
| Rotolo et al. | CAR-based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy | |
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| JP2016520074A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| HRP20210116T1 (hr) | Poboljšane kompozicije t stanica | |
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| MX367787B (es) | Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer. | |
| JP2017504601A5 (enExample) | ||
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2018504094A5 (enExample) | ||
| JP2018520679A5 (enExample) | ||
| JP2017535292A5 (enExample) |